II. AMENDMENTS TO THE CLAIMS

Claim 1. (Original) Use of an α -aminoamide of formula (I):

$$R-A \longrightarrow CH_2 - N - CH - CONHR_3$$
 (I)

wherein:

A is a - $(CH_2)_m$ - or - $(CH_2)_n$ -X-, wherein m is 1 or 2; n is zero, 1 or 2; and X is -O-, -S- or -NH-;

R is a furyl, thienyl, or pyridyl ring or a phenyl ring, unsubstituted or substituted by one or two substituents independently selected from halogen, hydroxy, C_1 - C_4 alkyl, C_1 - C_3 alkoxy and trifluoromethyl;

 R_1 is hydrogen or C_1 - C_3 alkyl;

 R_2 is hydrogen or C_1 - C_2 alkyl, unsubstituted or substituted by hydroxy or phenyl; phenyl, unsubstituted or substituted by one or two substituents independently selected from C_1 - C_3 alkyl, halogen, hydroxy, C_1 - C_2 alkoxy or trifluoromethyl; R_3 is hydrogen or C_1 - C_3 alkyl;

if the case, either as a single isomer, or as a mixture thereof, or a pharmaceutically acceptable derivative thereof; in the manufacture of a medicament for the treatment of head pain conditions.

Claim 2. (Original) Use of an α -aminoamide according to claim 1, wherein in formula (I):

A is a group selected from -CH₂-CH₂-, -CH₂-O-, -CH₂-S-, - CH₂-CH₂-O-; R is a phenyl ring, unsubstituted or substituted by one or two substituents independently selected from halogen, C₁-C₃ alkyl or a methoxy group; or a thienyl ring;

R₁ is hydrogen or C₁-C₂ alkyl;

R₂ is hydrogen or methyl, unsubstituted or substituted by hydroxy, or phenyl unsubstituted or substituted by C₁-C₂ alkyl, halogen, hydroxy, methoxy or trifluoromethyl; and

3

RPP/124357.1

R₃ is hydrogen or C₁-C₂ alkyl.

Claim 3. (Currently Amended) Use of an α -aminoamide according to claim 1 or 2, wherein in formula (I):

A is -CH2-O-, -CH2-S- or -CH2-CH2-;

R is a phenyl ring, unsubstituted or substituted by one or two halogen atoms;

R₁ is hydrogen;

R₂ is hydrogen or methyl, unsubstituted or substituted by hydroxy or phenyl ring, unsubstituted or substituted by a halogen atom; and

R₃ is hydrogen or methyl.

Claim 4. (Currently Amended) Use of an α -aminoamide according to claim 1, wherein the α -aminoamide is selected from the group consisting of:

- 2-(4-benzyloxybenzylamino)propanamide;
- 2-[4-(2-fluorobenzyloxy)benzylamino]propanamide;
- 2-[4-(2-chlorobenzyloxy)benzylamino]propanamide;
- 2-[4-(3-fluorobenzyloxy)benzylamino]propanamide;
- 2-[4-(3-chlorobenzyloxy)benzylamino]propanamide;
- 2-[4-(4-fluorobenzyloxy)benzylamino]propanamide;
- 2-[4-(2-fluorobenzyloxy)benzylamino]-N-methyl-propanamide;
- 2-[4-(3-fluorobenzyloxy)benzylamino]-N-methyl-propanamide;
- 2-[4-(2-fluorobenzyloxy)benzylamino]-3-hydroxy-propanamide;
- 2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-propanamide;
- $\hbox{2-(4-benzyloxybenzylamino)-3-hydroxy-N-methylpropanamide;}\\$
- 2-[4-(2-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;
- 2-[4-(2-chlorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;
- 2-[4-(3-fluorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;
- 2-[4-(3-chlorobenzyloxy)benzylamino]-3-hydroxy-N-methylpropanamide;
- 2-[4-(2-thienylmethylenoxy)benzylamino]-propanamide;
- 2-[4-(2-(3-fluorophenyl)ethyl)benzylamino)-propanamide;
- 2-[4-benzylthiobenzylamino)-propanamide;
- 2-[4-benzyloxybenzylamino]-3-phenyl-N-methylpropanamide;

RPP/124357.1 4

- 2-[4-benzyloxybenzylamino]-N-methylbutanamide;
- 2-[4-benzyloxybenzylamino]-2-phenyl-acetamide;
- 2-[4-(2-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide;
- 2-[4-(3-fluorobenzyloxy)benzylamino]-2-phenyl-acetamide;
- 2-[4-(3-chlorobenzyloxy)benzylamino]-2-phenyl-acetamide;
- 2-[4-(3-fluorobenzyloxy)benzylamino]-2-(2-fluorophenyl)acetamide;
- 2-[4-(3-fluorobenzyloxy)benzylamino]-2-(3-fluorophenyl)acetamide; and
- 2-[4-(3-chlorobenzyloxy)benzylamino]-2-(3-fluorophenyl)acetamide;

if the case, either as a single isomer or as a mixture thereof, or a pharmaceutically acceptable derivative thereof.

Claim 5. (Currently Amended) Use of an α-aminoamide according to any of the previous claims claim 1, wherein the α-aminoamide is selected from the group consisting of: (S)-(+)-2[4-(3-fluorobenzyloxy)benzylamino]-propanamide, (S)-(+)-2-[4-(3-chlorobenzyloxy) benzylamino]-propanamide and (S)-(+)-2-[4-(3-chlorobenzyloxy) benzylamino]-propanamide.

Claim 6. (Currently Amended) Use according to any of the previous claims claim 1, wherein the head pain conditions are involving a cerebral vasodilatation mechanism.

Claim 7. (Currently Amended) Use according to any of the previous claims claim 1, wherein head pain conditions are both primary and secondary headache disorders.

Claim 8. (Currently Amended) Use according to any of the previous claims claim 7, wherein the primary headache disorders derive from the intense pain of acute migraine or cluster headaches or from vascular mechanisms; and the secondary headache disorders derive from infection, metabolic disorders, or other systemic illnesses.

Claim 9. (Currently Amended) Use according to any of the previous claims claim 1, wherein head pain conditions include migraine, headache, neuralgia, hemicrania, facial pain and arachnoiditis.

Claim 10. (Currently Amended) Use according to any of the previous claims claim 9, claims, wherein migraine is acute, transformed or vascular migraine; headache is acute,

cluster, evolutive or tension type headache; neuralgia is trigeminal neuralgia; hemicrania is chronic paroxysmal hemicrania.

Claim 11. (Currently Amended) A method for the treatment of head pain conditions in a mammal in need thereof comprising administering to the mammal a therapeutically effective dose of at least one α-aminoamide of formula (I) as defined in any of claims 1 to 5 claim 1.

Claim 12. (Currently Amended) A method according to the previous claim, wherein the mammal is administered a dose of the for the treatment of head pain conditions in a mammal in need thereof comprising administering to the mammal a therapeutically effective dose of at least one α-aminoamide of formula (I) as defined in any of claims 1 to 5 claim 1 which ranges from about 0.05 to 20 mg/kg body weight per day.

Claim 13. (Currently Amended) A method according to claim 11 or 12, wherein the mammal is administered a dose of the for the treatment of head pain conditions in a mammal in need thereof comprising administering to the mammal a therapeutically effective dose of at least one α-aminoamide of formula (I) as defined in any of claims 1 to 5 claim 1 which ranges from about 0.5 to 10 mg/kg day.

Claim 14. (Currently Amended) A method according to any of claims from 11 to 13, wherein the mammal is administered a dose of the for the treatment of head pain conditions in a mammal in need thereof comprising administering to the mammal a therapeutically effective dose of at least one α-aminoamide of formula (1) as defined in any of claims 1 to 5 claim 1 which ranges from about 0.5 to 5 mg/kg day.

6

Claim 15. (Canceled).

45 eg + 4